Current attitude to deferral of cellular therapy or nontransplant chemotherapy due to SARS-CoV-2 asymptomatic infection: Survey of Infectious Diseases Working Party EBMT.
Jan StyczyńskiSimone CesaroMarie von Lilienfeld-ToalFrancesco MarchesiLidia GilMalgorzata MikulskaNina KnelangeLotus WendelDiana AverbuchRafael de la CamaraPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2022)
The objective of the study was to assess the current clinical practice and the attitude toward deferral of HCT/chemotherapy in patients with hematological diseases in cases of asymptomatic patients with a positive assay for SARS-CoV-2. In August 2021, we performed a survey among EBMT centers regarding their attitude toward deferral of HCT/chemotherapy in patients with a positive PCR result. Centers were willing to defer the planned cellular therapy for patients with asymptomatic SARS-CoV-2 infection without previous COVID-19 disease, and patients who became asymptomatic after a previous COVID19 disease but persistently shed the virus, respectively, in case of high-risk allo-HCT (90.2%/76.9%), low-risk allo-HCT for malignant diseases (88.2%/83.7%), allo-HCT for nonmalignant diseases (91.0%/91.0%), auto-HCT (88.0%/79.8%), and CAR-T therapy (83.1%/81.4%). The respective rates toward deferral of noncellular therapy patients was lower for both groups of patients, and varied with the primary diagnosis and anti-malignant treatment. There is a relatively high rate of willingness to defer treatment in asymptomatic patients being positive for SARS-CoV-2, planned for cellular therapy, regardless of previous history of vaccination or COVID-19. The same approach is presented for most of patients before noncellular therapy. Nevertheless, each patient should be considered individually weighting risks and benefits.
Keyphrases
- sars cov
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- coronavirus disease
- respiratory syndrome coronavirus
- prognostic factors
- stem cells
- clinical practice
- squamous cell carcinoma
- climate change
- radiation therapy
- mesenchymal stem cells
- signaling pathway
- bone marrow
- high throughput
- infectious diseases
- cell cycle arrest
- cell therapy
- combination therapy